Postoperative nausea and vomiting are common after recovery from anest
hesia. We examined the prophylactic effect of granisetron on postopera
tive nausea and vomiting in 120 female patients (ASA physical status I
) undergoing gynecologic surgery. They were randomly allocated to one
of three groups (n = 40 for each): saline (as a control), granisetron
20 mu g/kg, and granisetron 40 mu g/kg. Saline or granisetron was give
n intravenously (IV) over 5 min approximately 30 min before the end of
anesthesia. Nausea, vomiting, and safety assessments were performed d
uring the 24-h recovery period. For the 24-h period after surgery, the
number of emesis-free patients was significantly larger in the granis
etron groups than in the control group (83%, 78%, and 20% of patients
receiving granisetron 20 mu g/kg and 40 mu g/kg, and saline, respectiv
ely). Granisetron at both doses also was superior to the control for t
he prevention of over the 24-h study period (nausea visual analog scal
es at 24-h postsurgery: 49 mm, 17 mm, and 18 mm in the control, granis
etron 20 mu g/kg, and granisetron 40 mu g/kg groups, respectively). Fe
wer patients received ''rescue'' antiemetics in the granisetron groups
than in the control group (10%, 10%, and 43% of patients in granisetr
on 20 mu g/kg and 40 mu g/kg, and the control groups, respectively). T
he adverse events in the granisetron groups were similar to those in t
he control group. The administration of granisetron had no significant
effect on vital signs or clinical laboratory test profiles. Granisetr
on given at 20 or 40 mu g/kg IV during anesthesia appears to be a simp
le, effective, and safe method for preventing postoperative nausea and
vomiting.